Here are the 10-K annual reports from Prothena Corporation plc (PRTA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PRTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRTA filings page.
Prothena Corporation plc filed its annual report describing a late-stage biotechnology company focused on diseases caused by protein misfolding, particularly neurodegenerative and rare amyloid disorders. Its pipeline spans wholly owned and partnered antibody, small‑molecule and vaccine programs.
Key partnered assets include prasinezumab with Roche for Parkinson’s disease, coramitug with Novo Nordisk for ATTR cardiomyopathy, and BMS-986446 and PRX019 with Bristol Myers Squibb for Alzheimer’s and other neurodegenerative diseases. Early programs feature the CYTOPE® intracellular targeting platform, Alzheimer’s candidates PRX012 and PRX012‑TfR, and dual Aβ‑tau vaccine PRX123.
The company discontinued development of birtamimab after the Phase 3 AFFIRM‑AL trial failed to meet its endpoints and implemented an approximate 63% workforce reduction in 2025 to lower operating costs while continuing to support key collaborations and selected wholly owned projects.